Palatin Technologies, Inc. (OTCMKTS:PTNT – Get Free Report) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $9.07 and traded as high as $27.78. Palatin Technologies shares last traded at $27.78, with a volume of 24 shares changing hands.
Palatin Technologies Stock Performance
The business’s fifty day simple moving average is $15.22 and its 200-day simple moving average is $9.07. The firm has a market capitalization of $27.03 million, a PE ratio of -17.92 and a beta of 0.75.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Featured Articles
- Five stocks we like better than Palatin Technologies
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
